Individualized chemotherapy treatment for breast cancer: Is it necessary? Is it feasible?

Drug Resistance Updates

Volumn 7, Issue 6, 2004, Pages 325-331

  Pusztai, Lajos ^a   Rouzier, Roman ^a   Wagner, Peter ^a   Symmans, W Fraser ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Pharmacogenomics; Predictive markers

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; FEASIBILITY STUDY; GENETIC TRANSCRIPTION; HUMAN; INDIVIDUALIZATION; MOLECULAR BIOLOGY; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 14844320532     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2004.10.002     Document Type: Article

References (44)

1. K.S. Albain, S. Nag, G. Calderillo-Ruiz, and J.P. Jordaan Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival Proc. Am. Assoc. Clin. Oncol. 22 14S 2004 510 (Abstract)
2. M. Ayers, W.F. Symmans, J. Stec, A. Damokosh, E. Clark, and K. Hess Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer J. Clin. Oncol. 22 2004 2284 2293
3. R.C. Bast Jr., P. Ravdin, and D.F. Hayes 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J. Clin. Oncol. 19 2001 1865 1878
4. H.D. Bear, S. Anderson, A. Brown, R. Smith, E.P. Mamounas, and B. Fisher National Surgical Adjuvant Breast and Bowel Project Protocol B-27, 2003. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol. 21 2003 4165 4174
5. X. de Bolle, and C.D. Bayliss Gene expression technology Methods Mol. Med. 71 2003 135 146
6. H.J. Broxterman, J. Lankelma, and K. Hoekman Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences Drug Resist. Updat. 6 2003 111 127
7. T.A. Buchholz, D. Stivers, J. Stec, M. Ayers, J. Brown, A. Bolt, A.A. Sahin, F.W. Symmans, V. Valero, G.N. Hortobagyi, and L. Pusztai Global gene expression changes during neoadjuvant chemotherapy of human breast cancer Cancer J. 8 2002 461 468
8. J. Chang, T.J. Powles, D.C. Allred, S.E. Ashley, G.M. Clark, A. Makris, L. Assersohn, R.K. Gregory, C.K. Osborne, and M. Dowsett Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J. Clin. Oncol. 17 1999 3058 3063
9. J.C. Chang, E.C. Wooten, and A. Tsimelzon Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362 369
10. M.L. Citron, D.A. Berry, C. Cirrincione, C. Hudis, E.P. Winer, and W.J. Gradishar Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J. Clin. Oncol. 21 2003 1431 1439
11. J. Crown, V. Dieras, M. Kaufmann, G. von Minckwitz, S. Kaye, R. Leonard, M. Marty, J.L. Misset, B. Osterwalder, and M. Piccart Chemotherapy for metastatic breast cancer-report of a European expert panel Lancet Oncol. 3 2002 719 727
12. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomized trials Lancet 352 1999 930 942
13. I.F. Faneyte, J.G. Schrama, J.L. Peterse, P.L. Remijnse, S. Rodenhuis, and M.J. van de Vijver Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br. J. Cancer. 88 2003 406 412
14. M. Fornier, M. Risio, C. Van Poznak, and A. Seidman HER2 testing and correlation with efficacy of trastuzumab therapy Oncology (Hunt) 16 2002 1340 1348 (discussion, pp. 1352, 1355-1358)
15. V.A. Fusaro, and J.H. Stone Mass spectrometry-based proteomics and analyses of serum: a primer for the clinical investigator Clin. Exp. Rheumatol. 21 6 Suppl. 32 2003 S3 S14
16. M. Gasco, and T. Crook p53 family members and chemoresistance in cancer: what we know and what we need to know Drug Resist. Updat. 6 2003 323 328
17. L. Gianni Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer Proc. Am. Soc. Clin. Oncol. 22 14S 2004 501 (Abstract)
18. M.C. Green, A.U. Buzdar, and T. Smith Weekly paclitaxel followed by FAC in the neoadjuvant setting provides improved pathological complete remission rates compared to standard paclitaxel followed by FAC therapy. Preliminary results of an ongoing prospective randomized trial Proc. Am. Soc. Clin. Oncol. 20 33a 2001 129 (Abstract 129)
19. J. Hannemann, H.M. Oosterkamp, and C.A.J. Bosch Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer Proc. Am. Soc. Clin. Oncol. 22 14S 2004 502 (Abstract)
20. I.C. Henderson, D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, and S. Martino Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J. Clin. Oncol. 21 2003 976 983
21. G.N. Hortobagyi, D. Hayes, and L. Pusztai Integrating newer science into breast cancer prognosis and treatment. Molecular predictors and profiles Proc. Am. Soc. Clin. Oncol. 20 2002 191 202
22. W.P. Kuo, T.K. Jenssen, A.J. Butte, L. Ohno-Machado, and I.S. Kohane Analysis of matched mRNA measurements from two different microarray technologies Bioformatics 18 2002 405 412
23. J. Li, Z. Zhang, J. Rosenzweig, Y.Y. Wang, and D.W. Chan Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer Clin. Chem. 48 2002 1296 1304
24. WAF1/cip1 on apoptosis and sensitivity to cancer chemotherapy Drug Resist. Updat. 6 2003 183 195
25. J.M. Mariadason, D. Arango, and L.H. Augenlicht Customizing chemotherapy for colon cancer: the potential of gene expression profiling Drug Resist. Updat. 7 2004 209 218
26. R.A. McClelland, U. Berger, L.S. Miller, T.J. Powles, and R.C. Coombes Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy J. Clin. Oncol. 4 1986 1171 1176
27. D. Miles, G. von Minckwitz, and A.D. Seidman Combination versus sequential single-agent therapy in metastatic breast cancer Oncologist 7 Suppl. 6 2002 13 19
28. D. Modlich, H.-B. Priscak, M. Munnes, W. Audretsch, and H. Bojar Immediate gene expression changes after first course of neoadjuvant chemotherapy in patients with primary breast cancer disease Clin. Cancer Res. 10 2004 6418 6431
29. S. Mukherjee, P. Tamayo, and S. Rogers Estimating dataset size requirements for classifying DNA microarray data J. Comput. Biol. 10 2003 119 142
30. J.M. Nabholtz, J.M. Vannetzel, J.F. Llory, and P. Bouffette Advances in the use of taxanes in the adjuvant therapy of breast cancer Clin. Breast Cancer 4 2003 187 192
31. J. O'Shaughnessy, D. Miles, S. Vukelja, V. Moiseyenko, J.P. Ayoub, and G. Cervantes Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J. Clin. Oncol. 20 2002 2812 2823
32. T. Petit, M. Wilt, M. Velten, R. Millon, J.F. Rodier, and C. Borel Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur. J. Cancer. 40 2004 205 211
33. L. Pusztai, B.W. Gregory, K.A. Baggerly, B. Peng, J. Koomen, and H.M. Kuerer Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma Cancer 100 2004 1814 1822
34. M.D. Radmacher, L.M. McShane, and R. Simon A paradigm for class prediction using gene expression profiles J. Comput. Biol. 9 2002 505 511
35. S. Rozan, A. Vincent-Salomon, and B. Zafrani No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer Int. J. Cancer. 79 1998 27 33
36. D.J. Samson, J. Seidenfeld, K. Ziegler, and N. Aronson Chemotherapy sensitivity and resistance assays: a systematic review J. Clin. Oncol. 22 2004 3618 3630
37. D. Schrag, H.S. Garewal, H.J. Burstein, D.J. Samson, D.D. Von Hoff, and M.R. Somerfield ASCO Working Group on chemotherapy sensitivity and resistance assays. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays J. Clin. Oncol. 22 2004 3631 3638
38. R. Simon, M.D. Radmacher, and K. Dobbin Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification J. Natl. Cancer Inst. 95 2003 14 18
39. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
40. C. Sotiriou, T.J. Powles, and M. Dowsett Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer Breast Cancer Res. 4 2002 3
41. W.F. Symmans, M. Ayers, and E. Clark Fine needle aspiration and core needle biopsy samples of breast cancer provide similar total RNA yield, but different stromal gene expression profiles cancer Cancer 97 2003 2960 2971
42. P.K. Tan, T.J. Downey, E.L. Spitznagel Jr., P. Xu, D. Fu, D.S. Dimitrov, R.A. Lempicki, B.M. Raaka, and M.C. Cam Evaluation of gene expression measurements from commercial microarray platforms Nucleic Acids Res. 31 2003 5676 5684
43. I. Vasilevskaya, and P.J. O'Dwyer Role of Jun and Jun kinase in resistance of cancer cells to therapy Drug Resist. Updat. 6 2003 147 156
44. M. Yoshimoto Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer Proc. Am. Soc. Clin. Oncol. 22 14S 2004 500 (Abstract)